KEKerim Erer

Kerim Erer

*This is an algorithmically generated author record based on publicly available information.

Kerim Erer has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PRE- AND POST-TRANSPLANT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED ACUTE MYELOID LEUKEMIA

    by Keri̇m Erer, Rasim Şahin, Yavuz Katırcılar, Fatoş Tekelioğlu, Serdal Korkmaz

  • Open Access

    Risk Factors for Infectious Adverse Events in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Venetoclax Combinations: A Retrospective Single‐Centre Real‐World Experience

    by Olgu Erkin Çınar, Azade Kanat, Kerim Erer, Rasim Şahin, Esma Eryılmaz Eren, Esra Yıldızhan

    Background: Venetoclax‐based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern. Aims: This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real‐world setting. Methods and Results: We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low‐dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥ 2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥ 2 IAEs occurred, with an incidence of 1 per 121 patient‐days. Multivariate analysis identified prolonged neutropenia (days, OR = 1.037, p = 0.005) and interacting concomitant medications (OR = 9.99, p < 0.001) as independent risk factors for IAEs. The rate of invasive fungal infections was as low as 3.5%, and the use of antifungal or antibacterial prophylaxis was not associated with a reduction in the rate of IAEs. Conclusion: IAEs remain a substantial risk in venetoclax‐treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.

  • Open Access

    The Impact of Citrate-Based Dialysis Solution on the Efficacy of Hemodialysis

    by Kerim Erer, Cihan Uysal, Oktay Oymak

    Anticoagulation,citrate,dialysis solution,hemodialysis

  • Open Access

    RISK FACTORS FOR INFECTIOUS ADVERSE EVENTS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH VENETOCLAX COMBINATIONS: A RETROSPECTIVE SINGLE-CENTRE REAL-WORLD EXPERIENCE

    by Olgu Erkin Çınar, Azade Kanat, Kerim Erer, Rasim Şahin, Esma Eryılmaz Eren, Esra Yıldızhan

    Background: Venetoclax-based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern. Aims: This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real-world setting. Methods and Results: We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low-dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥2 IAEs occurred, with an incidence of 1 per 121 patient-days. Multivariate analysis identified prolonged neutropenia (days, OR=1.037, p=0.005) and interacting concomitant medications (OR=9.99, pConclusion: IAEs remain a substantial risk in venetoclax-treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.